

TELIX PARTNERS WITH FRENCH COMPANY ATONCO TO FIGHT BLADDER CANCER

Australian biopharmaceutical company Telix Pharmaceuticals Limited (ASX: TLX) has signed an agreement with France's ATONCO S.A.S to explore the use of Telix's Molecularly Targeted Radiation (MTR) technology.

The license and development agreement will allow ATONCO to explore the use of MTR technology for the treatment of non-muscle-invasive bladder cancer that is resistant to standard therapies.

Under the agreement, ATONCO will receive a license to select components of Telix's antibody portfolio for use with astatine-211, an alpha-emitting radioisotope, to treat bladder cancer that has become unresponsive to standard therapies.

Dr. Christian Behrenbruch, CEO of Telix, said astatine-211 emits alpha particles with a favorable emission profile that is well suited for bladder cancer because it delivers highly localized antitumor radiation with minimal impact on surrounding tissue.

Under the agreement, Telix can receive development milestone payments of approximately A\$30 millions, as well as royalties upon successful commercialization. Telix retains a right to reacquire the program if clinical data are conclusive.

This collaboration with ATONCO represents a new milestone for Telix, as it is the first time we have licensed our intellectual property to a third party," said Dr. Behrenbruch, "While we maintain a disciplined focus on our prostate, kidney and brain cancer programs, this collaboration demonstrates the attractiveness of our intellectual property to other companies and allows our assets to be developed for new cancer indications beyond Telix's core focus areas, while giving us the ability to re-annex the program if promising clinical data warrant."

Professor Jean-Francois Chatal, CEO of ATONCO, said the collaboration with Telix Pharmaceuticals is driven by the clinical potential of alpha immunotherapy for non-muscle-invasive refractory bladder cancer.

"This is truly a clinical indication with currently unmet therapeutic efficacy that could benefit from a new treatment through the antibody-targeted characteristics of astatine-211."

In 2018, bladder cancer was the fifth most common cancer in the United States, with an estimated 82,501 new cases diagnosed and 17,755 deaths resulting from bladder cancer. ATONCO is a privately held French company that develops radiopharmaceuticals for oncology applications. A spin-off of the world-class radiochemistry cluster that includes the University Hospital of Nantes and the ARRONAX Public Interest Group (GIP), ATONCO and its academic collaborators are dedicated to the clinical use of astatine-211.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using molecularly targeted radiation (MTR). The company is headquartered in Melbourne and has international offices in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX).

For more information, visit www.telixpharma.com

About ATONCO

ATONCO is a privately held French company developing molecularly targeted radiopharmaceuticals for oncology applications. Originating from the world-class nuclear medicine cluster in Nantes, ATONCO and its academic partners are committed to the clinical use of alpha emitting radionuclides, in particular astatine-211 (^{211}At).

For more information, visit www.atonco-pharma.com

Important Information This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available